Skip to main content
. 2017 Apr 21;21(9):2163–2171. doi: 10.1111/jcmm.13140

Figure 4.

Figure 4

Effects of melatonin and its receptor antagonist luzindole on proliferation and differentiation of NSCs under IL‐18 challenging. (A) mRNA and (B) protein expression of melatonin receptors of MT1 and MT2, respectively. (C) The proliferation of NSCs treated with IL‐18 and/or melatonin (10 ng/ml) in the absence or presence of luzindole (5 μM). (D) Effects of luzindole on neurosphere formation with or without IL‐18 and/or melatonin. (E) Immunofluorescence staining for β‐tubulin‐III‐positive neurons derived from NSCs treated as above. (F) mRNA and (G) protein levels of β‐tubulin‐III. *P < 0.05; ***P < 0.001.